Rituximab pharmacokinetics in children and adolescents with de novo intermediate and advanced mature B-cell lymphoma/leukaemia: A Children's Oncology Group report Academic Article uri icon


MeSH Major

  • Antibodies, Monoclonal, Murine-Derived
  • Antineoplastic Agents
  • Lymphoma, B-Cell


  • The ANHL01P1 trial was undertaken to determine pharmacokinetics and safety following the addition of rituximab to French-American-British/Lymphome Malins de Burkitt (FAB/LMB96) chemotherapy in 41 children and adolescents with Stage III/IV mature B-cell lymphoma/leukaemia. Patients received rituximab (375 mg/m(2) ) days -2 and 0 of two induction cycles and day 0 of two consolidation cycles. Highest peak levels were achieved following the second dose of each induction cycle [299 ± 19 and 384 ± 25 μg/ml (Group-B); 245 ± 31 and 321 ± 32 μg/ml (Group-C)] with sustained troughs and t½ of 26-29 d. Rituximab can be safely added to FAB chemotherapy with high early rituximab peak/trough levels and a long t½.

publication date

  • September 2013



  • Academic Article



  • eng

PubMed Central ID

  • PMC3745786

Digital Object Identifier (DOI)

  • 10.1111/bjh.12434

PubMed ID

  • 23802659

Additional Document Info

start page

  • 678

end page

  • 83


  • 162


  • 5